Ibrahim M. Sablaban
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ibrahim M. Sablaban has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Mauran Sivananthan
Department of Psychiatry, Wayne State University, Henry Ford Hospital, Detroit, Michigan, USA
2 shared publications- Adam J. Elder
Department of Dermatology, Wayne State University, Detroit, Michigan
1 shared publication Ankita Bachhawat Jaykumar
Hypertension and Vascular Research, Henry Ford Hospital, Detroit, Michigan
1 shared publicationBakhos A. Tannous
Experimental Therapeutics and Molecular Imaging Laboratory, Neuroscience Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
1 shared publicationBrittany Stallworth
Department of Psychiatry, Morehouse School of Medicine, Atlanta, GA
1 shared publicationDeepak Prabhakar
Department of Psychiatry, Henry Ford Hospital, Detroit, MI
1 shared publication
Latest Publications
- 14 March 2026
- Published by Wiley in Bipolar Disorders
- Vol. 28 (3) , e70108
Interaction of Fluoxetine and Caffeine in a Patient With Substance‐Induced Mania
Background: Substance‐induced manic episodes may occur in individuals without prior psychiatric illness and can be triggered by medications or stimulants. Selective serotonin reuptake inhibitors (SSRIs) and high caffeine intake have both been associated with mood destabilization. Aims: To describe a case of acute mania potentially precipitated by excessive fluoxetine use and high caffeine consumption. Materials & Methods: A 42‐year‐old male with no prior psychiatric history presented with symptoms of acute mania after recently starting fluoxetine and accidentally taking approximately twice the prescribed dose. Clinical evaluation, laboratory testing, urine drug screening, and collateral history were obtained. Results: The patient exhibited elevated mood, grandiosity, pressured speech, and decreased need for sleep. Laboratory results were unremarkable except for cannabis on urine drug screening. Fluoxetine was discontinued, and he was treated with valproate and adjunctive haloperidol during inpatient hospitalization, leading to improvement in symptoms. Discussion: The manic episode may have been triggered by excessive fluoxetine exposure combined with high caffeine intake. Fluoxetine may also inhibit CYP1A2, potentially increasing caffeine levels and amplifying stimulant effects. Conclusions: This case highlights a possible interaction between fluoxetine and caffeine contributing to mania and underscores the importance of assessing stimulant use and medication dosing when evaluating new‐onset manic symptoms.
- 14 March 2026
- Published by Wiley in Bipolar Disorders
- Vol. 28 (3) , e70108
Interaction of Fluoxetine and Caffeine in a Patient With Substance‐Induced Mania
Background: Substance‐induced manic episodes may occur in individuals without prior psychiatric illness and can be triggered by medications or stimulants. Selective serotonin reuptake inhibitors (SSRIs) and high caffeine intake have both been associated with mood destabilization. Aims: To describe a case of acute mania potentially precipitated by excessive fluoxetine use and high caffeine consumption. Materials & Methods: A 42‐year‐old male with no prior psychiatric history presented with symptoms of acute mania after recently starting fluoxetine and accidentally taking approximately twice the prescribed dose. Clinical evaluation, laboratory testing, urine drug screening, and collateral history were obtained. Results: The patient exhibited elevated mood, grandiosity, pressured speech, and decreased need for sleep. Laboratory results were unremarkable except for cannabis on urine drug screening. Fluoxetine was discontinued, and he was treated with valproate and adjunctive haloperidol during inpatient hospitalization, leading to improvement in symptoms. Discussion: The manic episode may have been triggered by excessive fluoxetine exposure combined with high caffeine intake. Fluoxetine may also inhibit CYP1A2, potentially increasing caffeine levels and amplifying stimulant effects. Conclusions: This case highlights a possible interaction between fluoxetine and caffeine contributing to mania and underscores the importance of assessing stimulant use and medication dosing when evaluating new‐onset manic symptoms.
- 3 April 2022
- Published by Taylor & Francis in Journal of Addictive Diseases
- Vol. 41 (2) , 181-184
Kratom & Stimulant Co-Addiction: A Case Series and Brief Review
Kratom (Mitragyna speciosa) is an easily accessible dietary supplement gaining notoriety in medicine for its use as a surrogate form of self-driven opioid use disorder treatment, albeit one with a lack of evidence and significant risks. Both misuse and withdrawal from kratom have been appreciated in the literature and addressed in a fashion analogous to that of opioids. Because of this, it has largely been studied through the looking glass of its properties of agonizing μ-opioid and likely α2-adrenergic receptors. While an important area of study, the correlation with kratom and stimulant use, reflected in the National Survey on Drug Use and Health, is one that often gets neglected clinically. In our manuscript we present three unique cases, demonstrative of the overlap kratom misuse may have with stimulant use disorders in distinct settings. We provide a discussion and review of this correlation in light of kratom use increasing in the United States.
- 3 April 2022
- Published by Taylor & Francis in Journal of Addictive Diseases
- Vol. 41 (2) , 181-184
Kratom & Stimulant Co-Addiction: A Case Series and Brief Review
Kratom (Mitragyna speciosa) is an easily accessible dietary supplement gaining notoriety in medicine for its use as a surrogate form of self-driven opioid use disorder treatment, albeit one with a lack of evidence and significant risks. Both misuse and withdrawal from kratom have been appreciated in the literature and addressed in a fashion analogous to that of opioids. Because of this, it has largely been studied through the looking glass of its properties of agonizing μ-opioid and likely α2-adrenergic receptors. While an important area of study, the correlation with kratom and stimulant use, reflected in the National Survey on Drug Use and Health, is one that often gets neglected clinically. In our manuscript we present three unique cases, demonstrative of the overlap kratom misuse may have with stimulant use disorders in distinct settings. We provide a discussion and review of this correlation in light of kratom use increasing in the United States.
- 1 March 2022
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 30 (6) , e554-e555
Apathy in Anoxic Brain Injury Treated With Bupropion
An abstract is unavailable. This article is available as a PDF only.
- 1 March 2022
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 30 (6) , e554-e555
Apathy in Anoxic Brain Injury Treated With Bupropion
An abstract is unavailable. This article is available as a PDF only.
- 3 December 2020
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 30 (10) , 620
Letter to the Editor: Treating Autism-Associated Sexual Compulsions with Naltrexone
Journal of Child and Adolescent Psychopharmacology
- 3 December 2020
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 30 (10) , 620
Letter to the Editor: Treating Autism-Associated Sexual Compulsions with Naltrexone
Journal of Child and Adolescent Psychopharmacology
- 12 September 2020
- Published by Taylor & Francis in Journal of Addictive Diseases
- Vol. 39 (1) , 138-139
The diagnosis of severe obsessions in the setting of kratom withdrawal and treatment with lorazepam: Case report
Commercially available Kratom (Mitragyna speciosa) is a dietary supplement that has gained popularity in the United States for its psychoactive effects and potential medicative properties as an opioid receptor agonist. Likewise, sudden discontinuation may be accompanied by an opioid-like withdrawal. We present the first case in the literature of the withdrawal manifesting in disturbing obsessive thoughts after the substance was used as an opioid replacement treatment by our patient, as well as the first case where lorazepam is utilized for mitigation of these thoughts.
- 12 September 2020
- Published by Taylor & Francis in Journal of Addictive Diseases
- Vol. 39 (1) , 138-139
The diagnosis of severe obsessions in the setting of kratom withdrawal and treatment with lorazepam: Case report
Commercially available Kratom (Mitragyna speciosa) is a dietary supplement that has gained popularity in the United States for its psychoactive effects and potential medicative properties as an opioid receptor agonist. Likewise, sudden discontinuation may be accompanied by an opioid-like withdrawal. We present the first case in the literature of the withdrawal manifesting in disturbing obsessive thoughts after the substance was used as an opioid replacement treatment by our patient, as well as the first case where lorazepam is utilized for mitigation of these thoughts.
- 3 August 2020
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 29 (6) , e747-e748
Attention-Deficit Hyperactivity Disorder–Associated Impulsive Aggression Treated With Lamotrigine
An abstract is unavailable. This article is available as a PDF only.
- 3 August 2020
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 29 (6) , e747-e748
Attention-Deficit Hyperactivity Disorder–Associated Impulsive Aggression Treated With Lamotrigine
An abstract is unavailable. This article is available as a PDF only.
- 31 January 2019
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 21 (1)
Escitalopram-Induced Rash
From the Primary Care Companion for CNS Disorders: Although SSRIs are not commonly associated with adverse skin reactions, some patients do experience serious cutaneous side effects from antidepressants. Here, read the case of Ms A, who developed a rash after starting escitalopram.
- 31 January 2019
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 21 (1)
Escitalopram-Induced Rash
From the Primary Care Companion for CNS Disorders: Although SSRIs are not commonly associated with adverse skin reactions, some patients do experience serious cutaneous side effects from antidepressants. Here, read the case of Ms A, who developed a rash after starting escitalopram.
- 17 January 2019
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 21 (1)
A Man Made Manic
Traumatic brain injury (TBI) has had increased notoriety in light of chronic traumatic encephalopathy in professional sports. However, despite the increased rate at which mood disorders affect this population, there remains little information on management of these disorders. TBI has also been implicated in the development of Parkinson disease, increasing the likelihood that patients may be treated with dopaminergic agents. Management of coexisting pathologies can become challenging, especially when confounded by medication side effects. A case is presented of a 58-year-old man who was admitted to the hospital in a manic state 15 years after having suffered a closed head injury. Several psychiatric admissions during the past 2 years were noted, with various diagnoses including different iterations of bipolar disorder. Among his medications, levodopa-carbidopa was present for an unsubstantiated Parkinson disease diagnosis. His mania resolved after discontinuation of the agent. This case is presented with a review of the relevant literature pertaining to the use of levodopa-carbidopa in this context, the use of other dopaminergic agents, and a biological hypothesis for the potential increased likelihood of manic symptoms in TBI patients who receive levodopa-carbidopa. Currently, there is a lack of research in this area, which emphasizes a need to review treatment guidelines for Parkinson disease patients with TBI.
- 17 January 2019
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 21 (1)
A Man Made Manic
Traumatic brain injury (TBI) has had increased notoriety in light of chronic traumatic encephalopathy in professional sports. However, despite the increased rate at which mood disorders affect this population, there remains little information on management of these disorders. TBI has also been implicated in the development of Parkinson disease, increasing the likelihood that patients may be treated with dopaminergic agents. Management of coexisting pathologies can become challenging, especially when confounded by medication side effects. A case is presented of a 58-year-old man who was admitted to the hospital in a manic state 15 years after having suffered a closed head injury. Several psychiatric admissions during the past 2 years were noted, with various diagnoses including different iterations of bipolar disorder. Among his medications, levodopa-carbidopa was present for an unsubstantiated Parkinson disease diagnosis. His mania resolved after discontinuation of the agent. This case is presented with a review of the relevant literature pertaining to the use of levodopa-carbidopa in this context, the use of other dopaminergic agents, and a biological hypothesis for the potential increased likelihood of manic symptoms in TBI patients who receive levodopa-carbidopa. Currently, there is a lack of research in this area, which emphasizes a need to review treatment guidelines for Parkinson disease patients with TBI.
- 1 November 2017
- Published by Elsevier in Psychosomatics
- Vol. 58 (6) , 664-668
Stiff Person Syndrome Presenting After the Initiation of Buspirone
- 1 November 2017
- Published by Elsevier in Psychosomatics
- Vol. 58 (6) , 664-668
Stiff Person Syndrome Presenting After the Initiation of Buspirone
- 15 January 2016
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 310 (2) , F183-F191
Real-time monitoring of NKCC2 endocytosis by total internal reflection fluorescence (TIRF) microscopy
The apical Na-K-2Cl cotransporter (NKCC2) mediates NaCl reabsorption by the thick ascending limb (TAL). The amount of NKCC2 at the apical membrane of TAL cells is determined by exocytic delivery, recycling, and endocytosis. Surface biotinylation allows measurement of NKCC2 endocytosis, but it has low time resolution and does not allow imaging of the dynamic process of endocytosis. We hypothesized that total internal reflection fluorescence (TIRF) microscopy imaging of labeled NKCC2 would allow monitoring of NKCC2 endocytosis in polarized Madin-Darby canine kidney (MDCK) and TAL cells. Thus we generated a NKCC2 construct containing a biotin acceptor domain (BAD) sequence between the transmembrane domains 5 and 6. Once expressed in polarized MDCK or TAL cells, surface NKCC2 was specifically biotinylated by exogenous biotin ligase (BirA). We also demonstrate that expression of a secretory form of BirA in TAL cells induces metabolic biotinylation of NKCC2. Labeling biotinylated surface NKCC2 with fluorescent streptavidin showed that most apical NKCC2 was located within small discrete domains or clusters referred to as “puncta” on the TIRF field. NKCC2 puncta were observed to disappear from the TIRF field, indicating an endocytic event which led to a decrease in the number of surface puncta at a rate of 1.18 ± 0.16%/min in MDCK cells, and a rate 1.09 ± 0.08%/min in TAL cells (n = 5). Treating cells with a cholesterol-chelating agent (methyl-β-cyclodextrin) completely blocked NKCC2 endocytosis. We conclude that TIRF microscopy of labeled NKCC2 allows the dynamic imaging of individual endocytic events at the apical membrane of TAL cells.
- 15 January 2016
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 310 (2) , F183-F191
Real-time monitoring of NKCC2 endocytosis by total internal reflection fluorescence (TIRF) microscopy
The apical Na-K-2Cl cotransporter (NKCC2) mediates NaCl reabsorption by the thick ascending limb (TAL). The amount of NKCC2 at the apical membrane of TAL cells is determined by exocytic delivery, recycling, and endocytosis. Surface biotinylation allows measurement of NKCC2 endocytosis, but it has low time resolution and does not allow imaging of the dynamic process of endocytosis. We hypothesized that total internal reflection fluorescence (TIRF) microscopy imaging of labeled NKCC2 would allow monitoring of NKCC2 endocytosis in polarized Madin-Darby canine kidney (MDCK) and TAL cells. Thus we generated a NKCC2 construct containing a biotin acceptor domain (BAD) sequence between the transmembrane domains 5 and 6. Once expressed in polarized MDCK or TAL cells, surface NKCC2 was specifically biotinylated by exogenous biotin ligase (BirA). We also demonstrate that expression of a secretory form of BirA in TAL cells induces metabolic biotinylation of NKCC2. Labeling biotinylated surface NKCC2 with fluorescent streptavidin showed that most apical NKCC2 was located within small discrete domains or clusters referred to as “puncta” on the TIRF field. NKCC2 puncta were observed to disappear from the TIRF field, indicating an endocytic event which led to a decrease in the number of surface puncta at a rate of 1.18 ± 0.16%/min in MDCK cells, and a rate 1.09 ± 0.08%/min in TAL cells (n = 5). Treating cells with a cholesterol-chelating agent (methyl-β-cyclodextrin) completely blocked NKCC2 endocytosis. We conclude that TIRF microscopy of labeled NKCC2 allows the dynamic imaging of individual endocytic events at the apical membrane of TAL cells.